Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

NCT06664502 is registered in ClinicalTrials.gov with EyeBiotech Ltd. as lead sponsor.

NCT NCT06664502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06664502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
Lead sponsor
EyeBiotech Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
November 12, 2024
Completion date
August 11, 2026
Enrollment
38 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

brvo - branch retinal vein occlusion, diabetic macular edema (dme), neovascular age-related macular degeneration (nvamd)